Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military

Journal of General Internal Medicine

Volumn 30, Issue 10, 2015, Pages 1406-1412

  Brzezniak, Christina ^a   Satram Hoang, Sacha ^b   Goertz, Hans Peter ^c   Reyes, Carolina ^c   Gunuganti, Ashok ^b   Gallagher, Christopher ^d   Carter, Corey A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b QD Research Inc   (United States)

^c GENENTECH INC   (United States)

^d WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

lung cancer; military; survival outcomes

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARMY; ARTICLE; ASIAN; CANCER MORTALITY; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; FEMALE; HISPANIC; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PACIFIC ISLANDER; RACE DIFFERENCE; TOBACCO USE; UNITED STATES; ADOLESCENT; ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; COHORT ANALYSIS; EPIDEMIOLOGY; ETHNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SOLDIER; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MILITARY PERSONNEL; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84942501393     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3280-z     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. American Cancer Society. Cancer Facts & Figures 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf [accessed February 26, 2015].
3. Surveillance Epidemiology and End Results (SEER). Stat bite: lung cancer stage at diagnosis in the United States, 1995–2001. J Natl Cancer Inst. 2005;97:1805.
4. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Lung carcinoma symptoms–an independent predictor of survival and an important mediator of African-American disparity in survival. Cancer. 2004;101:1655–63.
5. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol. 2004;57:597–609.
6. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125:27–37.
7. Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. Lung Cancer. 2005;47:165–72.
8. Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer. 1996;77:1947–55.
9. Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994;10:21–30.
10. Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst. 2002;94:284–90.
11. Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:407–12.
12. Bryant AS, Cerfolio RJ. Impact of race on outcomes of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:711–5.
13. McDavid K, Tucker TC, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med. 2003;163:2135–44.
14. Fergusson RJ, Thomson CS, Brewster DH, et al. Lung cancer: the importance of seeing a respiratory physician. Eur Respir J. 2003;21:606–10.
15. Fesinmeyer MD, Goulart B, Blough DK, Buchwald D, Ramsey SD. Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer. 2010;116:4810–6.
16. Hardy D, Xia R, Liu CC, Cormier JN, Nurgalieva Z, Du XL. Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients. Cancer. 2009;115:4807–18.
17. Zheng L, Enewold L, Zahm SH, et al. Lung cancer survival among black and white patients in an equal access health system. Cancer Epidemiol Biomarkers Prev. 2012;21:1841–7.
18. Saeed AM, Toonkel R, Glassberg MK, et al. The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the survival, epidemiology, and end results database. Cancer. 2012;118:4495–501.
19. Yang R, Cheung MC, Byrne MM, et al. Do racial or socioeconomic disparities exist in lung cancer treatment? Cancer. 2010;116:2437–47.
20. Sonobe M, Date H, Wada H, et al. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:788–95.
21. Brunelli A, Salati M, Refai M, et al. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:385–90 e1-2.
22. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.
23. Howlader N NA, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Available at: http://seer.cancer.gov/csr/1975_2009_pops09/ [accessed February 26, 2015].
24. Wang SJ, Fuller CD, Thomas CR Jr. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:180–90.
25. Gadgeel SM, Severson RK, Kau Y, Graff J, Weiss LK, Kalemkerian GP. Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest. 2001;120:55–63.
26. Jack RH, Gulliford MC, Ferguson J, Moller H. Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services? Br J Cancer. 2003;88:1025–31.
27. Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:25–31.
28. National Lung Screening Trial Research T, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–91.
29. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002;13:1087–93.
30. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.
31. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.
32. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.